Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP)’s share price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.29 and traded as high as $0.43. Tonix Pharmaceuticals shares last traded at $0.43, with a volume of 420 shares traded.
TNXP has been the subject of several recent research reports. ValuEngine raised shares of Tonix Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, September 5th. Roth Capital lowered their price target on shares of Tonix Pharmaceuticals from $4.00 to $1.30 and set a “buy” rating for the company in a research note on Friday, August 30th.
The business’s 50-day simple moving average is $0.44 and its 200-day simple moving average is $1.27. The stock has a market cap of $6.91 million, a PE ratio of -0.02 and a beta of 1.30. The company has a quick ratio of 6.92, a current ratio of 6.92 and a debt-to-equity ratio of 0.01.
Several hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. purchased a new position in shares of Tonix Pharmaceuticals in the second quarter valued at about $117,000. A.R.T. Advisors LLC purchased a new position in shares of Tonix Pharmaceuticals in the second quarter valued at about $42,000. Finally, Acadian Asset Management LLC increased its position in shares of Tonix Pharmaceuticals by 620.0% in the second quarter. Acadian Asset Management LLC now owns 65,632 shares of the company’s stock valued at $89,000 after acquiring an additional 56,516 shares during the period. Hedge funds and other institutional investors own 2.46% of the company’s stock.
About Tonix Pharmaceuticals (NASDAQ:TNXP)
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense. Its lead product candidate is Tonmyar (TNX-102 SL), a proprietary low-dose cyclobenzaprine and sublingual tablet as a bedtime administration, which is in Phase III development for the treatment of posttraumatic stress disorder (PTSD) and Fibromyalgia; and Phase II development for the treatment of agitation in Alzheimer's disease.
Further Reading: How to build a Fibonacci channel
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.